Dr. D’Angelo on Future Directions With CAR T-Cell Therapy in Lymphoma

Video

Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.

Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses advances made with CAR T-cell therapy in lymphoma.

Recently, it has been possible to achieve durable remissions and complete responses with CAR T-cell therapy in this patient population, D’Angelo says. This could indicate that this modality may represent a potential curable approach for a refractory population, according to D’Angelo.

Safer CAR T-cell products with increased efficacy and complete, durable responses, are anticipated, D'Angelo notes.

Additionally, the emergence of novel CAR T-cell therapy combinations with agents such as lenalidomide (Revlimid) and ibrutinib (Imbruvica), possess potential, D’Angelo concludes. 

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.